Stephanie Wissel, Felix Buder, Joseph C Larson, Xiaonan Xue, Ruby Greywoode, Michael Böhm, Longjian Liu, Robert Wallace, Ludwig Kramer, Jean Wactawski-Wende, Marcia L Stefanick, Lesley F Tinker, Lisa Warsinger Martin, Charles P Mouton, Michael J LaMonte, Sylvia Wassertheil-Smoller, Bernhard Haring
{"title":"Time-in-Target Range, Blood Pressure Variability and Risk of Ischemic Colitis in Older Women.","authors":"Stephanie Wissel, Felix Buder, Joseph C Larson, Xiaonan Xue, Ruby Greywoode, Michael Böhm, Longjian Liu, Robert Wallace, Ludwig Kramer, Jean Wactawski-Wende, Marcia L Stefanick, Lesley F Tinker, Lisa Warsinger Martin, Charles P Mouton, Michael J LaMonte, Sylvia Wassertheil-Smoller, Bernhard Haring","doi":"10.1093/ajh/hpag136","DOIUrl":"https://doi.org/10.1093/ajh/hpag136","url":null,"abstract":"<p><strong>Background: </strong>The association of blood pressure (BP) with ischemic colitis (IC) remains uncertain. We examined whether time in BP target range and visit-to-visit BP variability (BPV) were associated with incident IC.</p><p><strong>Methods: </strong>We analyzed 36,584 postmenopausal women aged ≥65 years from the Women's Health Initiative Clinical Trials. BP was measured annually over approximately 8 years. Time in Target Range (TTR) was estimated as the proportion of follow-up time with SBP between 110 and <130 mmHg. BPV was defined as standard deviation (SD) of the participant's mean BP across visits. IC cases were identified via Medicare claims through 2022. Multivariable Cox models were fitted separately by antihypertensive medication use.</p><p><strong>Results: </strong>Over a mean follow-up of 12.4 years, 1,238 IC cases occurred. Compared with ≥80% TTR, <20% TTR was associated with higher IC risk among women taking antihypertensive medication (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.12-1.73) but not among those not taking it (HR 1.03, 95% CI 0.65-1.63). The highest versus lowest systolic BPV quartile was associated with higher IC risk among women taking (HR 1.68, 95% CI 1.24-2.27) and not taking antihypertensive medication (HR 1.83, 95% CI 1.09-3.08). For diastolic BPV, HRs were 1.60 (95% CI 1.22-2.11) among women taking and 0.97 (95% CI 0.60-1.55) among women not taking antihypertensives.</p><p><strong>Conclusions: </strong>Among older women taking antihypertensive medication, lower time in the systolic BP target range was associated with higher IC risk, whereas greater systolic BPV was associated with higher risk irrespective of treatment.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149416823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fátima Coronado, Adam S Vaughan, Susan A Carlson, Namita Joshi, Michael Schooley, Letitia Presley-Cantrell
{"title":"Two Decades of Cardiovascular Prevention Science at CDC: A Bibliometric Analysis, 2006-2025.","authors":"Fátima Coronado, Adam S Vaughan, Susan A Carlson, Namita Joshi, Michael Schooley, Letitia Presley-Cantrell","doi":"10.1093/ajh/hpag133","DOIUrl":"https://doi.org/10.1093/ajh/hpag133","url":null,"abstract":"<p><strong>Background: </strong>The Centers for Disease Control and Prevention's Division for Heart Disease and Stroke Prevention (DHDSP) provides national leadership for cardiovascular disease (CVD) prevention, including efforts to improve hypertension control. Scientific publications document surveillance, program implementation, evaluation, and dissemination of evidence-based strategies. This study describes DHDSP's scientific productivity, focus, and reach across two decades of CVD prevention work.</p><p><strong>Methods: </strong>We conducted a bibliometric analysis of publications authored or coauthored by DHDSP staff during 2006-2025. Publications were identified from internal records and PubMed searches, verified for eligibility, and categorized by condition and topic area. Citation metrics, Relative Citation Ratio (RCR), Altmetric Attention Scores, policy and guideline mentions, authorship role, and collaboration indicators were summarized descriptively.</p><p><strong>Results: </strong>DHDSP contributed to 841 publications ranging annually from 12 in 2006 to 67 in 2017. Publications accrued 88,636 citations (median: 19; 25-75 percentiles: 7;48). Median RCR was 1.15 (25-75 percentiles: 0.50-2.53), and median Altmetric Attention Score was 6.0 (25-75 percentiles: 0.5-23.5). DHDSP publications were cited or mentioned in 637 policy documents and 410 guidelines indexed by Altmetric. Most focused on core DHDSP conditions, including hypertension, with surveillance and epidemiology the most common topic. Overall, 240 publications (28.5%) included a focus on hypertension.</p><p><strong>Conclusions: </strong>DHDSP's publication portfolio demonstrates sustained scientific productivity and broad dissemination across two decades of CVD prevention. Hypertension was an important component, alongside research addressing heart disease, stroke, and other cardiovascular risk factors and outcomes. The portfolio documents the evolution of public health science and contributes to the evidence base for cardiovascular disease prevention and control.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association of A Body Shape Index, But Not Body Mass Index, with Seated Arterial Stiffness Evaluated by Innovative Cardio-Ankle Vascular Index.","authors":"Kazuhiro Shimizu, Akihiro Ogawa, Daiji Nagayama, Tomoyuki Yamamoto, Satoshi Kawakami, Masahiro Iwakawa, Shuji Sato, Hiroshi Mikamo, Toshio Kinoshita, Kohji Shirai","doi":"10.1093/ajh/hpag128","DOIUrl":"https://doi.org/10.1093/ajh/hpag128","url":null,"abstract":"<p><strong>Background: </strong>A Body Shape Index (ABSI) reflects abdominal adiposity independent of body size. Although the cardio-ankle vascular index (CAVI) is linked to ABSI, whether this association extends to innovative CAVI (iCAVI) remains unclear. We developed iCAVI, an arterial stiffness index measured from the aortic valve to the right brachial artery in the seated position and examined its association with ABSI.</p><p><strong>Methods: </strong>This cross-sectional study included 117 individuals undergoing cardiovascular risk assessment. iCAVI, ABSI, body mass index (BMI), and waist circumference (WC) were evaluated. Associations were assessed using Spearman's correlation and multivariable analyses adjusting for age and sex-adjusted analyses, with further adjustment for hypertension, diabetes mellitus, dyslipidemia, and coronary artery disease. Adjusted iCAVI values across anthropometric tertiles were compared.</p><p><strong>Results: </strong>iCAVI was positively correlated with ABSI (ρ = 0.233, 95% CI [0.048, 0.402], p = 0.012), but not with WC (ρ = -0.054, 95% CI [-0.238, 0.134], p = 0.563) or BMI (ρ = -0.162, 95% CI [-0.339, 0.026], p = 0.081). Age- and sex-adjusted iCAVI increased across ABSI tertiles (2.79, 2.96, and 3.14; p for trend = 0.045). The linear contrast estimate was 0.25 (95% CI [0.01, 0.49]) and remained similar after further adjustment for hypertension, diabetes, dyslipidemia, and coronary artery disease (0.23, 95% CI [-0.02, 0.48]; p for trend = 0.067).</p><p><strong>Conclusions: </strong>ABSI was positively associated with iCAVI, whereas BMI and WC were not, suggesting that ABSI may capture aspects of body shape associated with arterial stiffness that are not reflected by conventional anthropometric indices.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Newly Reported Major Diagnoses and Subsequent Self-Reported Hypertension Treatment Status in Korean Adults Aged 50 Years or Older.","authors":"Renjie Huang, Miao Huang, Rui Zhang","doi":"10.1093/ajh/hpag129","DOIUrl":"https://doi.org/10.1093/ajh/hpag129","url":null,"abstract":"<p><strong>Background: </strong>The association between a newly reported major diagnosis and subsequent self-reported hypertension-treatment status remains uncertain.</p><p><strong>Methods: </strong>We analyzed seven overlapping periods of three visits approximately 2 years apart in the Korean Longitudinal Study of Ageing (2006-2008-2010 through 2018-2020-2022). Eligibility required age ≥50 years, physician-diagnosed hypertension at Visit 1, and reported antihypertensive medication use or hypertension treatment at Visits 1 and 2. Newly reported diabetes, cancer, stroke, heart disease, or chronic lung disease was assessed at Visit 2. The Visit 3 outcome was a report of no current hypertension treatment, including no antihypertensive medication use. Modified-Poisson regression used participant-clustered standard errors. The adjusted absolute risk difference was defined as the standardized probability with a newly reported diagnosis minus that without one.</p><p><strong>Results: </strong>Among 13,579 observation periods from 3,581 participants, 932 included a newly reported diagnosis. Adjusted probabilities of no reported treatment were 7.5% with and 8.4% without a newly reported diagnosis. The adjusted risk ratio for not receiving treatment for hypertension, including antihypertensive medication, associated with a newly reported diagnosis was 0.89 (95% confidence interval 0.71-1.13); the adjusted absolute risk difference (newly reported diagnosis minus no newly reported diagnosis) was -0.90 percentage points (95% confidence interval -2.66 to 0.85).</p><p><strong>Conclusions: </strong>A newly reported major diagnosis was not associated with self-reported antihypertensive medication use or hypertension treatment approximately 2 years later.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Estimated Pulse Wave Velocity, Immediate Antihypertensive Treatment, and Clinical Outcomes After Acute Ischemic Stroke.","authors":"Bizhong Che, Jiaxin Zan, Daoxia Guo, Xiaowei Zheng, Zhengbao Zhu, Chongke Zhong, Hao Peng, Tian Xu, Aili Wang, Tan Xu, Youfa Wang, Yonghong Zhang","doi":"10.1093/ajh/hpag131","DOIUrl":"https://doi.org/10.1093/ajh/hpag131","url":null,"abstract":"<p><strong>Background: </strong>Whether estimated pulse wave velocity (ePWV) influences the effect of early antihypertensive treatment in acute ischemic stroke remains unclear.</p><p><strong>Methods: </strong>This study was a post hoc analysis of the China Antihypertensive Trial in Acute Ischemic Stroke conducted in 2009-2013. ePWV was calculated using age and mean blood pressure on admission. The primary outcome was a composite of death or major disability at 14 days or hospital discharge and 3 months after stroke. We examined the association between ePWV and the primary outcome and tested for the interaction between ePWV and early blood pressure-lowering treatment.</p><p><strong>Results: </strong>Among the 4058 and 3975 participants included in the 14-day or hospital discharge and 3-month analyses, respectively, 1364 (33.6%) and 1001 (25.2%) experienced the composite outcome of death or major disability. The multivariable-adjusted risk ratios (95% CIs) for the highest (≥12.7 m/s) versus lowest ePWV tertile (<11.1 m/s) were 1.23 (1.06-1.43) for the composite outcome of death or major disability and 2.87 (1.10-5.39) for death at 14 days or hospital discharge (P for trend<0.05). At 3 months, the adjusted risk ratios (95% CIs) were 1.41 (1.17-1.70), 3.91 (2.02-7.57), and 2.33 (1.33-4.07) for the composite outcome of death or major disability, death, and vascular events, respectively. There were no significant differences in clinical outcomes between the early antihypertensive treatment and control groups across ePWV tertiles.</p><p><strong>Conclusions: </strong>: Higher ePWV was associated with worse clinical outcomes after acute ischemic stroke, and ePWV did not modify the effect of early antihypertensive treatment.</p><p><strong>Registration: </strong>-URL: https://www.clinicaltrials.gov; Unique identifier: NCT01840072.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tasfia Hussain, Stephen P Juraschek, Edgar R Miller, Frank M Sacks, Paul R Conlin, Laura Svetkey, Thomas Moore, Lawrence J Appel
{"title":"The effects of sodium reduction and the DASH diet on ambulatory blood pressure: overall and race-stratified results from the DASH-Sodium trial.","authors":"Tasfia Hussain, Stephen P Juraschek, Edgar R Miller, Frank M Sacks, Paul R Conlin, Laura Svetkey, Thomas Moore, Lawrence J Appel","doi":"10.1093/ajh/hpag079","DOIUrl":"10.1093/ajh/hpag079","url":null,"abstract":"<p><strong>Background: </strong>On average, Black adults compared to White adults have higher ambulatory blood pressure (ABP), particularly during sleep.</p><p><strong>Methods: </strong>Participants were randomly assigned to eat a control diet or the DASH diet (n = 335 with ABP, 58% self-reported Black). On their assigned diet, participants had 3, randomly ordered, 30-day feeding periods with different sodium levels (low, intermediate, and high). ABP was obtained at the end of each period.</p><p><strong>Results: </strong>Compared to the control diet with high sodium (reference), reducing sodium and consuming the DASH diet, alone or combined, significantly lowered 24-hour, awake, and asleep systolic and diastolic ABP in Black and Non-Black participants. The DASH diet with low sodium reduced mean (95%CI) awake SBP by 9.0 mmHg (6.4, 11.7) in Black participants and 7.5 mmHg (4.5, 10.6) in Non-Black participants, and mean asleep SBP by 8.0 mmHg (4.8, 11.2) in Black participants and 7.4 mmHg (3.9,11.0) in Non-Black participants in comparison to the reference (each P < .05). Despite reductions in asleep ABP from the DASH diet and sodium reduction, significant differences by race persisted in achieved ABP, consistently so for asleep ABP. Mean ± SE achieved levels of asleep SBP on the control diet with high sodium were 124.1 ± 0.6 mmHg in Black participants and 120.2 ± 0.7 mmHg in Non-Black participants (P < .005), while on the DASH diet with low sodium, achieved levels were 115.2 ± 0.5 mmHg in Black participants and 112.5 ± 0.7 mmHg in Non-Black participants (P < .005).</p><p><strong>Conclusions: </strong>Despite clinically relevant reductions in ABP from sodium reduction and the DASH diet in both Black and Non-Black participants, racial differences in achieved levels of asleep ABP persisted.</p><p><strong>Clinical trial registration: </strong>Trial Number NCT00000608.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"1324-1333"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elizabeth C S Swart, Tiffany Lee, Malamo Countouris, Samuel K Peasah, Urvashi Patel, Arundhathi Jeyabalan, Chester B Good
{"title":"Antihypertensive medication use and prescription discontinuation among postpartum women.","authors":"Elizabeth C S Swart, Tiffany Lee, Malamo Countouris, Samuel K Peasah, Urvashi Patel, Arundhathi Jeyabalan, Chester B Good","doi":"10.1093/ajh/hpag043","DOIUrl":"10.1093/ajh/hpag043","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is common during and after pregnancy. Patterns of antihypertensive medication discontinuation (AMD) in the postpartum period are not well characterized. This study examined factors associated with AMD among postpartum women.</p><p><strong>Methods: </strong>A retrospective claims analysis was conducted using the Komodo Health Healthcare Map. The study included 63,312 postpartum women aged 18-64 years who delivered between January 1, 2019, and December 31, 2022, and initiated an antihypertensive medication within 30 days after live delivery. AMD was defined as the absence of any anti-hypertensive medication from the index medication (days' supply + 30-day). Multivariable Poisson regression models with a log link and robust variance estimators were used.</p><p><strong>Results: </strong>Discontinuation occurred in 57.8% (36,576) of women. In adjusted analyses, older age was associated with lower risk of AMD compared with women aged 18-24 years (relative risk [RR], 0.93; 95% CI, 0.93-0.94 for ages 25-34; RR, 0.89; 95% CI, 0.88-0.90 for ages 35-44; RR, 0.85; 95% CI, 0.82-0.88 for ages ≥45). Hispanic (RR, 1.03; 95% CI, 1.02-1.04) and Asian (RR, 1.02; 95% CI, 1.01-1.04) women had a higher risk of discontinuation compared with White women. Women with eclampsia (RR, 0.97; 95% CI, 0.97-0.98), baseline hypertension (RR 0.95, 95% CI, 0.95-0.96), and postpartum depression (RR, 0.95; 95% CI, 0.94-0.96) had a lower risk of discontinuation.</p><p><strong>Conclusions: </strong>Postpartum AMD was common in this national claims-based cohort. Differences across demographic and clinical subgroups highlight patient populations that may benefit from directed postpartum blood pressure follow-up and medication management.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"1292-1300"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147985963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The mediating role of sleep blood pressure in the association between B-type natriuretic peptide and cardiovascular events: The Nagahama Study.","authors":"Yasuharu Tabara, Kimihiko Murase, Takeshi Matsumoto, Takahisa Kawaguchi, Tomoko Wakamura, Toyohiro Hirai, Kazuo Chin, Fumihiko Matsuda","doi":"10.1093/ajh/hpag124","DOIUrl":"https://doi.org/10.1093/ajh/hpag124","url":null,"abstract":"<p><strong>Background: </strong>B-type natriuretic peptide (BNP) is a risk marker for not only heart failure but also cardiovascular diseases (CVD). This study investigated the possible mediating role of sleep blood pressure (BP) in the association between BNP and CVD events.</p><p><strong>Methods: </strong>Data for 5,751 participants were obtained from the Nagahama Study, a longitudinal cohort study of the general Japanese population. Circulating BNP levels were determined from blood specimens. BP was measured at home in the morning and evening, and three times per night during sleep using a timer-equipped cuff-oscillometric device.</p><p><strong>Results: </strong>During the mean follow-up period of 9.4 years (54,350 person-years), 169 CVD cases were observed (Incidence rate: 31.1 per 10,000 person-year, 95% confidence interval [CI]: 26.7, 36.2). BNP levels ≥40 pg/mL were independently associated with CVD. The sleep BP-adjusted hazard ratio of high BNP for CVD was 1.80 (95% CI: 1.18, 2.74), while the awake home BP-adjusted hazard ratio was 1.92 (95% CI: 1.26, 2.91). Causal mediation analysis indicated a greater mediation rate of sleep SBP (14.3%, 95% CI: -2.8, 31.3) than awake home SBP (5.8%, 95% CI; -2.6, 14.2) in the association between BNP and CVD incidence. Factors associated with log-normalized BNP levels were age, sex, body mass index, sleep SBP, and nocturnal urination frequency.</p><p><strong>Conclusion: </strong>Prognostic significance of BNP for CVD events was partially mediated by BP particularly BP during sleep.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M T Caputo, K Lakshminarayan, B Sakboonyarat, S M Westberg, S A Everson-Rose, T McCarthy, C Streib, P Drawz, T A Murray
{"title":"Cost-effectiveness analysis of an mHealth intervention to improve hypertension control in patients with elevated cardiovascular risk.","authors":"M T Caputo, K Lakshminarayan, B Sakboonyarat, S M Westberg, S A Everson-Rose, T McCarthy, C Streib, P Drawz, T A Murray","doi":"10.1093/ajh/hpag127","DOIUrl":"https://doi.org/10.1093/ajh/hpag127","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the cost-effectiveness of a mobile health technology (mHealth) based care model to facilitate home blood pressure (BP) monitoring and remote hypertension management.</p><p><strong>Methods: </strong>We used a Markov microsimulation model to study health and cost outcomes for three hypertension control strategies: an mHealth-based care model (mGlide) vs. Enhanced Usual Care (EUC) vs. No-Intervention. We sampled patient characteristics from the mGlide randomized controlled trial (RCT) and randomly transitioned patients through three possible health states over a 10-year horizon with monthly cycles: 1) No Cardiovascular Event, 2) Cardiovascular Event, and 3) Deceased. We determined transition probabilities from literature, allowing the probabilities to vary by patient characteristics, including BP values. We evaluated health and cost outcomes across a range of plausible deterministic treatment effects (expected BP reductions) supported by the RCT. We performed probabilistic sensitivity analysis to assess cost-effectiveness while randomly varying the treatment effect magnitude.</p><p><strong>Results: </strong>The mHealth-based care model was cost-effective compared to No-Intervention and EUC across all deterministic scenarios. 10-year mortality absolute risk reductions ranged from 4.9-5.8% (vs No-Intervention) and 0.6-3.3% (vs EUC) across scenarios. In probabilistic sensitivity analysis, mHealth-based care (vs EUC) was less costly in 59.6% of iterations and had better health outcomes in 99.6%. Comparing all care models, mHealth-based care had the greatest net monetary benefit in 95% of iterations at $26,000/QALY and in 99% of iterations at $72,000/QALY.</p><p><strong>Conclusions: </strong>In the current study, we estimated that mHealth-based care models can be cost-effective approaches to improve hypertension control in patients with elevated cardiovascular risk.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}